2008
Cost analysis of clinic and office-based treatment of opioid dependence: Results with methadone and buprenorphine in clinically stable patients
Jones ES, Moore BA, Sindelar JL, O’Connor P, Schottenfeld RS, Fiellin DA. Cost analysis of clinic and office-based treatment of opioid dependence: Results with methadone and buprenorphine in clinically stable patients. Drug And Alcohol Dependence 2008, 99: 132-140. PMID: 18804923, PMCID: PMC2646001, DOI: 10.1016/j.drugalcdep.2008.07.013.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBuprenorphineCohort StudiesCost of IllnessCosts and Cost AnalysisData Interpretation, StatisticalFemaleHealth PersonnelHumansMaleMethadoneMiddle AgedNarcoticsOpioid-Related DisordersPhysicians' OfficesSocioeconomic FactorsSubstance Abuse DetectionSubstance Abuse Treatment CentersTreatment OutcomeYoung AdultConceptsOffice-based treatmentOpioid dependencePatient costsClinical contactMonthly medication costsOffice-based buprenorphineOffice-based methadoneMonths of treatmentAnalysis of treatmentTotal monthly costsChi-square testMonths of maintenanceStable patientsMedication costsPatientsMethadoneMonthly costBuprenorphineTreatmentMonthsStatistical comparisonCost estimatesClinic
2007
Clinic Variation in the Cost‐Effectiveness of Contingency Management
Olmstead TA, Sindelar JL, Petry NM. Clinic Variation in the Cost‐Effectiveness of Contingency Management. American Journal On Addictions 2007, 16: 457-460. PMID: 18058410, PMCID: PMC3072219, DOI: 10.1080/10550490701643062.Peer-Reviewed Original ResearchCost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease
Rosenheck RA, Leslie DL, Sindelar JL, Miller EA, Tariot PN, Dagerman KS, Davis SM, Lebowitz BD, Rabins P, Hsiao JK, Lieberman JA, Schneider LS. Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease. JAMA Psychiatry 2007, 64: 1259-1268. PMID: 17984395, DOI: 10.1001/archpsyc.64.11.1259.Peer-Reviewed Original ResearchConceptsCost-benefit analysisSecond-generation antipsychoticsGreatest net health benefitNet benefit analysisNet health benefitWholesale priceHealth Utilities Index Mark 3Economic perspectiveAlzheimer's diseaseBenefit approachHealth care costsTotal health costsHealth costsQALYsCare costsMeasures of effectivenessPlacebo-controlled trialLower health care costsHealth service useTotal health careMeasures of functionCostTreatment of psychosisQuality of lifeSensitivity analysisCost‐effectiveness of prize‐based contingency management in methadone maintenance treatment programs
Sindelar JL, Olmstead TA, Peirce JM. Cost‐effectiveness of prize‐based contingency management in methadone maintenance treatment programs. Addiction 2007, 102: 1463-1471. PMID: 17645428, PMCID: PMC3072844, DOI: 10.1111/j.1360-0443.2007.01913.x.Peer-Reviewed Original ResearchConceptsPrize-based contingency managementUsual careContingency managementStimulant-negative urine samplesUrine samplesNational Drug Abuse Treatment Clinical Trials NetworkTreatment programMethadone maintenance treatment programIncremental costBaseline urine samplesMulti-site clinical trialMaintenance treatment programMethadone maintenance clinicsClinical Trials NetworkCommunity treatment programsCost-effectiveness studiesCost of treatmentCost-effectiveness analysisPresence of stimulantsCM conditionClinical trialsCommunity clinicsMaintenance clinicsEffectiveness trialTreatment outcomesThe cost‐effectiveness of four treatments for marijuana dependence
Olmstead TA, Sindelar JL, Easton CJ, Carroll KM. The cost‐effectiveness of four treatments for marijuana dependence. Addiction 2007, 102: 1443-1453. PMID: 17645430, PMCID: PMC2398724, DOI: 10.1111/j.1360-0443.2007.01909.x.Peer-Reviewed Original ResearchConceptsMET/CBTDrug counselingContingency managementPatient outcomesYoung adultsEffective treatmentMarijuana dependenceAcceptability curvesIncremental cost-effectiveness ratioRandomized clinical trialsCost of therapyPatient outcome measuresCost-effective dependsCost-effectiveness ratioSubstance abuse clinicsCost-effective treatmentCM procedureClinical trialsOutcome measuresUrine specimenUrine specimensAdditional weeksAdditional studiesMarijuana abstinenceLonger duration
2006
Effectiveness of Switching Antipsychotic Medications
Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA. Effectiveness of Switching Antipsychotic Medications. American Journal Of Psychiatry 2006, 163: 2090-2095. PMID: 17151159, DOI: 10.1176/ajp.2006.163.12.2090.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntipsychotic AgentsBenzodiazepinesCross-Over StudiesDibenzothiazepinesDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleHumansMiddle AgedOlanzapinePatient DropoutsPsychotherapyQuetiapine FumarateResearch DesignRisperidoneSchizophreniaSchizophrenic PsychologySelection BiasSurvival AnalysisTreatment OutcomeConceptsMedication changesDifferent antipsychoticsCause treatment discontinuationCurrent medication regimensClinical Antipsychotic TrialsPhase 1 analysisPhase 1 findingsBaseline medicationsSwitching medicationsTreatment discontinuationMedication regimensPrimary outcomeMedication effectivenessAntipsychotic medicationAntipsychotic TrialsMedicationsAntipsychoticsClinical situationsOlanzapinePatientsRisperidoneIntervention effectivenessDearth of informationDiscontinuationRandom assignmentCost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia
Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J. Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia. American Journal Of Psychiatry 2006, 163: 2080-2089. PMID: 17151158, DOI: 10.1176/ajp.2006.163.12.2080.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntipsychotic AgentsChronic DiseaseCost-Benefit AnalysisDrug CostsFollow-Up StudiesHealth Care CostsHumansLongitudinal StudiesMiddle AgedPatient DropoutsPerphenazinePsychiatric Status Rating ScalesQuality-Adjusted Life YearsResearch DesignSchizophreniaSchizophrenic PsychologyTreatment OutcomeCost-effectiveness of prize-based incentives for stimulant abusers in outpatient psychosocial treatment programs
Olmstead TA, Sindelar JL, Petry NM. Cost-effectiveness of prize-based incentives for stimulant abusers in outpatient psychosocial treatment programs. Drug And Alcohol Dependence 2006, 87: 175-182. PMID: 16971054, PMCID: PMC1950254, DOI: 10.1016/j.drugalcdep.2006.08.012.Peer-Reviewed Original ResearchConceptsUsual careStimulant abusersClinical trialsPatient outcomesNational Drug Abuse Treatment Clinical Trials NetworkDrug abuse treatment clinicsAbstinence-based incentivesIncremental cost-effectiveness ratioUsual care groupPrimary patient outcomeRandomized clinical trialsClinical Trials NetworkPsychosocial treatment programCost-effectiveness ratioCost-effectiveness analysisCare groupTreatment clinicsStimulant abstinenceAcceptability curvesAbstinence timeTreatment programTrials NetworkIncremental costCareIncentive group
2005
The role of depression symptoms in predicting drug abstinence in outpatient substance abuse treatment
Dodge R, Sindelar J, Sinha R. The role of depression symptoms in predicting drug abstinence in outpatient substance abuse treatment. Journal Of Substance Use And Addiction Treatment 2005, 28: 189-196. PMID: 15780549, DOI: 10.1016/j.jsat.2004.12.005.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmbulatory CareComorbidityConnecticutCross-Sectional StudiesDepressionFemaleFinancing, GovernmentHumansMaleMiddle AgedMotivationPatient CompliancePatient DischargePublic AssistanceRegression AnalysisSecondary PreventionSocioeconomic FactorsSubstance Abuse DetectionSubstance-Related DisordersTreatment OutcomeConceptsLength of staySubstance abuse treatment outcomesOutpatient substance abuse treatmentSubstance abuse treatmentDepressive symptomsInsurance statusTreatment outcomesAbstinence statusDepression symptomsDrug useDrug abstinenceAbuse treatmentReal-world clinical settingHigher depressive symptom scoresOutpatient substance abuse treatment programsDepressive symptom scoresSubstance abuse treatment programsSymptom scoresTreatment characteristicsPrimary drugDecreased likelihoodReferral sourceClinical settingSymptomsTreatment program
2004
Cost effectiveness of disulfiram Treating cocaine use in methadone-maintained patients
Jofre-Bonet M, Sindelar JL, Petrakis IL, Nich C, Frankforter T, Rounsaville BJ, Carroll KM. Cost effectiveness of disulfiram Treating cocaine use in methadone-maintained patients. Journal Of Substance Use And Addiction Treatment 2004, 26: 225-232. PMID: 15063917, PMCID: PMC3662046, DOI: 10.1016/s0740-5472(04)00004-2.Peer-Reviewed Original ResearchConceptsMethadone treatmentClinical trialsCocaine useDouble-blind clinical trialCocaine dependenceStandard methadone treatmentBlind clinical trialMethadone-maintained patientsRandomized clinical trialsOpioid-dependent subjectsMethadone-maintained opiate addictsStandard treatmentOutcome measuresOpioid addictsPromising treatmentOpiate addictsIncremental costDisulfiramAdditional treatmentNumber of daysTrialsTreatmentCost effectivenessEconomic evaluationAddicts
2002
Benefit‐Cost Analysis of Addiction Treatment: Methodological Guidelines and Empirical Application Using the DATCAP and ASI
French MT, Salomé HJ, Sindelar JL, McLellan AT. Benefit‐Cost Analysis of Addiction Treatment: Methodological Guidelines and Empirical Application Using the DATCAP and ASI. Health Services Research 2002, 37: 433-455. PMID: 12036002, PMCID: PMC1430361, DOI: 10.1111/1475-6773.031.Peer-Reviewed Original ResearchConceptsDrug Abuse Treatment Cost Analysis ProgramBenefit-cost analysisEconomic evaluationEconomic benefitsFuture economic researchTotal economic benefitTotal economic costFuture economic evaluationsEconomic researchDetailed methodological guidelinesEmpirical applicationConsecutive fiscal yearsSensitivity analysisOutpatient drug-free programsEconomic costsMethodological guidelinesFiscal yearCost dataSubsequent sensitivity analysisDrug-free programsResource useMethodological foundationsBenefitsCostEstimates